Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.

Scientific reports - 25 Oct 2016

Chang Sui-Yuan, Lin Pi-Han, Cheng Chien-Lin, Chen Mao-Yuan, Sun Hsin-Yun, Hsieh Szu-Min, Sheng Wang-Huei, Su Yi-Ching, Su Li-Hsin, Chang Shu-Fang, Liu Wen-Chun, Hung Chien-Ching, Chang Shan-Chwen

Abstract excerpt

Antiretroviral therapy containing an integrase strand transfer inhibitor (INSTI) plus two NRTIs has become the recommended treatment for antiretroviral-naive HIV-1-infected patients in the updated guidelines. We aimed to determine the prevalence of INSTI-related mutations in Taiwan. Genotypic resistance assays were performed on plasma from ARV-naïve patients (N = 948), ARV-experienced but INSTI-naive patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase Inhibitors

Share to Phylogeny

Share to Prevalence

Share to Raltegravir Potassium

Share to Taiwan

Source

Open in PubMed Open full text

Identifiers

PMID: 27779200
DOI: 10.1038/srep35779
PMCID: PMC5078839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.PMID 27779200Read ↗

Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.Semantic proximity Read ↗

Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).Semantic proximity Read ↗

Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.Semantic proximity Read ↗

Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infectionSemantic proximity Read ↗

Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.Semantic proximity Read ↗

Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.Semantic proximity Read ↗

Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China.Semantic proximity Read ↗

Drug Resistance to Integrase Strand-Transfer Inhibitors among HIV-1-Infected Adults in Guangdong, ChinaSemantic proximity Read ↗

Short Communication: Trends in Transmitted Drug Resistance in Treatment-Naive HIV Patients in Korea.Semantic proximity Read ↗

Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIVSemantic proximity Read ↗

HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients.Semantic proximity Read ↗

Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.